Loading…
Ligand Pharmaceuticals Incorporated is projected to rise to $466.77 by 2027, a +48% move from its current price of $316.24. LGND is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $310.25 | $316.55 | $322.98 | +0.10% |
| Jul 13 | $307.97 | $316.86 | $326.00 | +0.20% |
| Jul 14 | $306.31 | $317.17 | $328.41 | +0.29% |
| Jul 15 | $304.96 | $317.48 | $330.51 | +0.39% |
| Jul 16 | $303.81 | $317.79 | $332.40 | +0.49% |
| Jul 17 | $302.80 | $318.10 | $334.16 | +0.59% |
| Jul 18 | $301.91 | $318.41 | $335.81 | +0.68% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $301.91 | $318.41 | $335.81 | +0.68% |
| Week 2 | $297.35 | $320.59 | $345.64 | +1.37% |
| Week 3 | $294.36 | $322.78 | $353.95 | +2.07% |
| Week 4 | $292.18 | $324.99 | $361.49 | +2.77% |
| Week 5 | $290.51 | $327.22 | $368.56 | +3.47% |
| Week 6 | $289.20 | $329.46 | $375.33 | +4.18% |
| Week 7 | $288.15 | $331.72 | $381.86 | +4.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ligand Pharmaceuticals Incorporated is a healthcare biopharmaceutical company that develops and licenses biopharmaceutical assets worldwide.
It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company was incorporated in 1987 and is based in Jupiter, Florida.
LGND is a healthcare stock currently trading at $319.55 with a market capitalization of $6.4B and a market rank of 1159. The price outlook shows a bullish trajectory across the forecast horizon, with the 2026 average price at $319.55 and the long horizon pointing to meaningful upside. By 2030 the average price is projected to $729.64, with a max of $1,019.28, and by 2040 and 2050 the averages rise to $2,723.18 and $5,962.26 respectively, underscoring a strong expected appreciation.
The forecast also implies rising upside through 2040 and 2050, with 2040 and 2050 averages indicating substantial gains relative to today. The 30-day range and near-term momentum in the forecast context support a bullish stance over the medium term.
A major floor 39.1% below — a decisive break under it would weaken the trend.
The nearest floor, 27.3% below — buyers have tended to step in here.
Price is pressing into resistance (2.0% away) — a breakout level to watch.
A major ceiling 20.9% above — clearing it would confirm fresh momentum.
Key LGND support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LGND market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $318.72 | Sell | $317.31 | Sell |
| MA 10 | $315.89 | Buy | $311.03 | Buy |
| MA 20 | $291.90 | Buy | $294.88 | Buy |
| MA 50 | $253.25 | Buy | $264.51 | Buy |
| MA 100 | $230.62 | Buy | $240.55 | Buy |
| MA 200 | $211.13 | Buy | $213.33 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 71.05 | Sell |
| Stoch RSI (14) | 32.90 | Neutral |
| CCI (20) | 66.53 | Neutral |
| Williams %R (14) | -10.54 | Info |
| MACD (12,26,9) | 0.75 | Buy |
| ROC (12) | 13.17 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 89.46 | Sell |
| TRIX (15) | 1.16 | Buy |
| Awesome (5,34) | 50.29 | Buy |
| Ultimate (7,14,28) | 60.11 | Neutral |
| Momentum (10) | 20.32 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 319.45 | Sell |
| ADX (14) | 45.42 | Buy |
| ATR (14) | 5.62 | Info |
The 30-day technical picture is bullish. RSI14 is 80, signaling strong momentum. The 50-day simple moving average is $244.59 and the 200-day simple moving average is $207.36, placing the price above both moving averages on a bullish backdrop.
The key near-term levels are a support at $217.75 and a resistance at $319.55, with the 30-day range spanning from $276.55 to $369.24.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $181.65 | $316.24 | $446.67 | 0% | Neutral | |
| $380.67 | $466.77 | $599.56 | +48% | Bullish | |
| $433.51 | $542.28 | $716.53 | +71% | Bullish | |
| $502.35 | $638.80 | $863.09 | +102% | Bullish | |
| $572.98 | $739.20 | $1,017.77 | +134% | Bullish | |
| $628.63 | $821.66 | $1,150.19 | +160% | Bullish | |
| $830.47 | $1,098.69 | $1,561.10 | +247% | Bullish | |
| $985.43 | $1,318.51 | $1,899.02 | +317% | Bullish | |
| $1,018.49 | $1,377.38 | $2,008.79 | +336% | Bullish | |
| $1,146.08 | $1,565.76 | $2,310.30 | +395% | Bullish | |
| $1,929.59 | $2,759.03 | $4,276.51 | +772% | Bullish | |
| $3,896.83 | $6,012.32 | $10,023.17 | +18.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $181.65 | $316.24 | $377.85 | +0.00% |
| August 2026 | $283.95 | $332.84 | $398.93 | +5.25% |
| September 2026 | $293.38 | $345.65 | $417.71 | +3.85% |
| October 2026 | $292.93 | $346.63 | $421.83 | +0.28% |
| November 2026 | $294.65 | $349.96 | $428.38 | +0.96% |
| December 2026 | $304.53 | $362.94 | $446.67 | +3.71% |
Click any year to see its month-by-month LGND forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ligand Pharmaceuticals Incorporated's 2026 outlook centres on $316.24, within a $181.65 to $446.67 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, LGND could reach as high as $599.56, with a base case around $466.77 and support toward $380.67 — roughly +48% from $316.24. Buyers look set to stay in control over this stretch.
Expect LGND to range from $433.51 to $716.53 through 2028. The $542.28 average target implies a +71% move from current prices. That is up +16% on the projected 2027 average. Momentum favours further upside here.
The LGND price prediction for 2029 points to an average of $638.80 (low $502.35, high $863.09) — a potential gain of +102% on today's $316.24. Buyers look set to stay in control over this stretch.
In 2030, LGND is projected to trade between $572.98 and $1,017.77, averaging $739.20 — a potential gain of +134% from today's $316.24. That is up +16% on the projected 2029 average. Momentum favours further upside here.
Ligand Pharmaceuticals Incorporated's 2031 outlook centres on $821.66, within a $628.63 to $1,150.19 range. That is up +11% on the projected 2030 average. That marks a +160% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, LGND could reach as high as $1,561.10, with a base case around $1,098.69 and support toward $830.47 — roughly +247% from $316.24. Momentum favours further upside here.
Expect LGND to range from $985.43 to $1,899.02 through 2033. The $1,318.51 average target implies a +317% move from current prices. That is up +20% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The LGND price prediction for 2034 points to an average of $1,377.38 (low $1,018.49, high $2,008.79) — a potential gain of +336% on today's $316.24. Momentum favours further upside here.
In 2035, LGND is projected to trade between $1,146.08 and $2,310.30, averaging $1,565.76 — a potential gain of +395% from today's $316.24. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Ligand Pharmaceuticals Incorporated's 2040 outlook centres on $2,759.03, within a $1,929.59 to $4,276.51 range. That is up +76% on the projected 2035 average. That marks a +772% change versus current levels. Momentum favours further upside here.
By 2050, LGND could reach as high as $10,023.17, with a base case around $6,012.32 and support toward $3,896.83 — roughly +18.0x from $316.24. Buyers look set to stay in control over this stretch.
Investing $1,000 in LGND today (≈ 3.162155 LGND) could be worth
$19,011.88
+$18,011.88 (+1801%) by 2050 · US Dollar
Based on the average projected LGND price of $6,012.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LGNDwould be worth at today's price.
$1,000 invested in LGND on Jul 10, 2025 (≈ 8.00128 LGND) would be worth
$2,530.32
+$1,530.32 (+153.0%) today · 2.53× · US Dollar
Based on a LGND entry price of $124.98 vs. today's $316.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $319.55 | $989.64 | -1.0% |
| 1 month ago | $248.24 | $1,273.93 | +27.4% |
| 3 months ago | $204.92 | $1,543.24 | +54.3% |
| 6 months ago | $206.81 | $1,529.13 | +52.9% |
| 1 year ago | $124.98 | $2,530.32 | +153.0% |
| All time (5.0y) ago | $78.83 | $4,011.81 | +301.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LGND forecast.
Our base-case forecast reaches $630.00 around 2029.
Implied market cap at $630.00: $12.63B
The multi-year forecast shows a bullish trajectory with steadily higher averages and substantial upside. In 2027 the avg is $464.88 with a 45.5% ROI and bullish sentiment. In 2028 the avg rises to $544.67 with a 70.5% ROI and bullish sentiment, and in 2029 the avg is $637.04 with a 99.3% ROI and bullish sentiment.
By 2030 the avg is $729.64 with a 128.3% ROI and bullish sentiment. The forecast continues to 2040 with an avg of $2,723.18 and a 752.2% ROI, and to 2050 with an avg of $5,962.26 and a 1765.8% ROI, both bullish. These figures illustrate a strong, albeit uncertain, path ahead.
Tap a question to reveal the answer.
2030 avg $729.64; min $559.14; max $1,019.28; ROI 128.3%; sentiment BULLISH.
Forecasts show bullish sentiment for 2027 onward with rising averages, such as 2027 avg $464.88 and 2030 avg $729.64, and soaring ROIs up to 1765.8% by 2050, though these are estimates.
Yes—the max forecast price in 2030 is $1,019.28, and the 2032 max is $1,595.40, indicating potential to exceed $1,000 within the forecast horizon.
Current price is $319.55 and market cap is $6.4B; rank 1159.
2040 avg $2,723.18; min $1,862.28; max $4,317.49; ROI 752.2%; sentiment BULLISH. 2050 avg $5,962.26; min $3,744.58; max $10,213.54; ROI 1765.8%; sentiment BULLISH.
Ligand Pharmaceuticals Incorporated Community Discussion
0Share your Ligand Pharmaceuticals Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.